Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. News
  7. Summary
    ALKS   IE00B56GVS15

ALKERMES PLC

(ALKS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alkermes : BofA Securities Downgrades Alkermes to Underperform from Neutral, Adjusts Price Target to $27 from $22

09/02/2021 | 09:33am EDT


© MT Newswires 2021
All news about ALKERMES PLC
04:01pALKERMES : to Report Third Quarter 2021 Financial Results on Oct. 27, 2021
PR
10/19ALKERMES : Announces Commercial Availability of LYBALVI for the Treatment of Schizophrenia..
AQ
10/18ALKERMES : Says Antipsychotic Drug Lybalvi is Available by Prescription in the US
MT
10/18Alkermes Announces Commercial Availability of Lybalvi® for the Treatment of Schizophren..
CI
09/23ALKERMES : New Survey Provides Insights Into Drinking Behaviors During the Pandemic
AQ
09/22ALKERMES : to Take Part in the Cantor Virtual Global Healthcare Conference
PR
09/22ALKERMES : New Survey Provides Insights Into Drinking Behaviors During the Pandemic
PR
09/13ALKERMES : to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleuki..
PR
09/10ALKERMES : Announces Launch of 4th Annual Alkermes Pathways Research Awards Program
AQ
09/09ALKERMES : Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program
PR
More news
Analyst Recommendations on ALKERMES PLC
More recommendations
Financials (USD)
Sales 2021 1 170 M - -
Net income 2021 -81,5 M - -
Net cash 2021 384 M - -
P/E ratio 2021 -62,7x
Yield 2021 -
Capitalization 5 003 M 5 003 M -
EV / Sales 2021 3,95x
EV / Sales 2022 3,47x
Nbr of Employees 2 245
Free-Float 96,7%
Chart ALKERMES PLC
Duration : Period :
Alkermes plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 31,01 $
Average target price 28,38 $
Spread / Average Target -8,50%
EPS Revisions
Managers and Directors
Richard F. Pops Chairman & Chief Executive Officer
Iain Michael Brown Senior VP, Chief Financial & Accounting Officer
Craig C. Hopkinson Chief Medical Officer & EVP-Research & Development
Thomas Harvey Chief Information Officer & Senior VP-IT
Sondra Smyrnios Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALKERMES PLC55.44%5 003
MODERNA, INC.219.34%134 660
LONZA GROUP AG27.07%58 240
IQVIA HOLDINGS INC.38.99%47 715
SEAGEN INC.-0.54%31 691
CELLTRION, INC.-39.00%25 332